Susanne Walz

TL;DR: MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface: the innate immune regulator CD47 (cluster of differentiation 47) and the adaptive immune checkpoint PD-L1 (programmed death–ligand 1).

TL;DR: Changes in MYC levels activate and repress specific sets of direct target genes that are characteristic of MYC-transformed tumour cells that have considerable prognostic value, suggesting that different cellular responses to physiological and oncogenic MyC levels are controlled by promoter affinity.

TL;DR: Mathematical modeling showed that binding affinities for interactions of MYC with DNA and with core promoter-bound factors are sufficient to explain promoter occupancies observed in vivo, explaining why tumor-specific MYC levels induce specific gene expression programs and alter defined biological properties of cells.

TL;DR: It is shown here that HUWE1 is required for growth of colorectal cancer cells in culture and in orthotopic xenograft models and identified a novel principle that allows for inhibition of MYC function in tumor cells.

TL;DR: It is shown that a small-molecule inhibitor of eIF4A inhibits MYC expression and suppresses tumor growth in vivo, and it is proposed that targeting translation initiation is a promising strategy to limit MyC expression in colorectal tumors.